Patents Issued in May 2, 2017
  • Patent number: 9636383
    Abstract: A synthetic platelet includes a biocompatible flexible nanoparticle that includes an outer surface and a plurality of peptides conjugated to the surface, the peptides including a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and an active platelet GPIIb-IIIa-binding peptides (GBPs).
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 2, 2017
    Assignee: Case Western Reserve University
    Inventors: Anirban Sen Gupta, Madhumitha Ravikumar
  • Patent number: 9636384
    Abstract: This document relates to methods and materials involved in delivering molecules to a mammal. For example, methods and materials for using nanoparticles to increase the half-life and the bioavailability of molecules administered to a mammal are provided.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: May 2, 2017
    Assignee: Mayo Foundation For Medical Education and Research
    Inventors: Christopher B. Eckman, Aimee R. Herdt
  • Patent number: 9636385
    Abstract: Provided is a method of treatment for reducing fibrosis involving administering purified collagenase into an anterior chamber of an eye of a human patient.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: May 2, 2017
    Assignee: The Research Foundation for The State University of New York
    Inventor: Robert Honkanen
  • Patent number: 9636386
    Abstract: Provided herein are attenuated Salmonella bacteria for expressing autoantigen alone or in combination with an immunomodulator, as well as methods of using these bacteria to treat various autoimmune disorders.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: CITY OF HOPE
    Inventors: Mohamed I. Husseiny Elsayed, Kevin Ferreri
  • Patent number: 9636387
    Abstract: The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: May 2, 2017
    Assignee: Governing Council of the University of Toronto
    Inventors: Aws Abdul-Wahid, Jean Gariépy
  • Patent number: 9636388
    Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: May 2, 2017
    Assignee: MORPHOGENESIS, INC.
    Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous
  • Patent number: 9636389
    Abstract: The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: May 2, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers
  • Patent number: 9636390
    Abstract: A vaccine for protection against multiple serotypes of Shigella sp., comprising a putative heat shock protein (EL PGI II), and Hypothetical Protein (EL PGIV) is provided.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: May 2, 2017
    Assignees: Indian Council of Medical Research, Post Graduate Institute of Medical Education and Research (PGIMER)
    Inventors: Neelam Taneja, Sapna Pahil, Meera Sharma
  • Patent number: 9636391
    Abstract: Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is then formulated for mucosal or pulmonary delivery to a subject. The pharmaceutical compositions are useful for preventing or treating mycobacterium-associated infections in a subject, including a human subject.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: May 2, 2017
    Assignee: Mico Bio, Inc.
    Inventors: Jason Fisher, Jennifer Lighter
  • Patent number: 9636392
    Abstract: The present invention provides an improved method of producing a capsular polysaccharide having a pneumococcal serotype. The method according to the present invention includes a step of additionally culturing bacterial cells producing a pneumococcal serotype without pH adjustment, thereby removing a protein precipitation process by acidification with a pH adjuster.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: May 2, 2017
    Assignee: SK CHEMICAL CO., LTD.
    Inventors: Jin-Hwan Shin, Mahn-Hoon Park, Hun Kim, Myeong-Ju Noh, Su-Jin Park
  • Patent number: 9636393
    Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli
  • Patent number: 9636394
    Abstract: A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (TRITON X-100™) to the resulting split virus preparation; and (iv) filtering the split virus preparation.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: May 2, 2017
    Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, GLAXOSMITHKLINE BIOLOGICALS, NIEDERLASSUNG DER SMITHKLINE BEECHAM PHARMA GMBH & CO KG.
    Inventors: Erik Jozef D'Hondt, Hans Bernd Engelmann
  • Patent number: 9636395
    Abstract: The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: May 2, 2017
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Anne Gauvrit, Frédéric Tangy, Marc Gregoire
  • Patent number: 9636396
    Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: May 2, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD XI, INSITUT GUSTAVE ROUSSY, VIROXIS S.A.S.
    Inventor: Thierry Heidmann
  • Patent number: 9636397
    Abstract: The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and a DNA component. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: May 2, 2017
    Assignee: Vaxliant, LLC
    Inventors: Timothy J Miller, Mary Ann Pfannenstiel
  • Patent number: 9636398
    Abstract: Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: May 2, 2017
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Gangamani S. Beligere, Shamila Manoj, Elaine M. Brate, Frank C. Grenier, David J. Hawksworth, Robert N. Ziemann, Larry G. Birkenmeyer, Bernhard Mueller, Andreas Popp, Susan Brophy
  • Patent number: 9636399
    Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: May 2, 2017
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
  • Patent number: 9636400
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: May 2, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • Patent number: 9636401
    Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: May 2, 2017
    Assignee: Microspherix LLC
    Inventor: Edward J. Kaplan
  • Patent number: 9636402
    Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: May 2, 2017
    Assignee: Microspherix LLC
    Inventor: Edward J. Kaplan
  • Patent number: 9636403
    Abstract: A composition for treating ear infections in animals includes an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, and an acid dissolved to form a liquid. The acid aids in keeping the steroidal anti-inflammatory agent in solution, and enhances the bactericidal effect of the composition. The method of preparing such composition includes dissolving the antifungal agent, steroidal anti-inflammatory agent, and acid in dehydrated alcohol, dissolving the antibiotic agent in propylene glycol, combining the two solutions together, heating the combination and then cooling the composition. Several drops of the composition are applied at least twice per day to the affected area of the animal's ear.
    Type: Grant
    Filed: August 1, 2011
    Date of Patent: May 2, 2017
    Assignee: Diamondback Drugs of Delaware, L.L.C.
    Inventors: Rory J Albert, Michael R. Blaire
  • Patent number: 9636404
    Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: May 2, 2017
    Assignee: Vision Global Holdings Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Man Kin Wong, Cornelia Wing Yin Man
  • Patent number: 9636405
    Abstract: A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of less than 0.9 or about 0.9 to about 0.7 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: May 2, 2017
    Assignee: FOAMIX PHARMACEUTICALS LTD.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Patent number: 9636406
    Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: May 2, 2017
    Assignee: Intensity Therapeutics, Inc.
    Inventor: Lewis H. Bender
  • Patent number: 9636407
    Abstract: A caspofungin composition includes caspofungin acetate and at least one amino acid, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, caspofungin acetate and the amino acid(s), and lyophilizing the liquid mixture.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 2, 2017
    Assignee: FRESENIUS KABI USA, LLC
    Inventors: John Zhiqiang Jiang, Arunya Usayapant, David Bowman, Keith Kwok, Joel Peterson
  • Patent number: 9636408
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 9636409
    Abstract: Covalent conjugates of an ?,?-disubstituted glycine ester and a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid and the ?,?-disubstituted glycine ester is conjugated to the modulator at a position remote from the binding interface between the inhibitor and the target enzyme or receptor pass into cells and the active acid hydrolysis product accumulates within the cells, as in the following compound:
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: May 2, 2017
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Alan Hastings Drummond, Alan Hornsby Davidson, David Festus Charles Moffat, Alastair David Graham Donald, Stephen John Davies
  • Patent number: 9636410
    Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: May 2, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Luis Brito, Michelle Chan, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Patent number: 9636411
    Abstract: Described herein are processes of making biocompatible water-soluble polymers conjugates. In particular, large scale processes of making poly(L-?-glutamyl-glutamate) conjugates that can be useful for a variety of drug delivery applications are described herein.
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: May 2, 2017
    Assignee: Nitto Denko Corporation
    Inventors: Hao Bai, Kwok Yin Tsang, Yi Jin, Lei Yu
  • Patent number: 9636412
    Abstract: Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson-Phillips
  • Patent number: 9636413
    Abstract: The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 2, 2017
    Assignee: ENDOCYTE, INC.
    Inventors: Iontcho Radoslavov Vlahov, Joseph Anand Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson, Marilynn Vetzel, Christopher Paul Leamon
  • Patent number: 9636414
    Abstract: The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 2, 2017
    Assignee: BIONTECH AG
    Inventor: Steve Pascolo
  • Patent number: 9636415
    Abstract: A molecule or molecule complex capable of binding to TLR9 and to CD32 comprising at least one epitope of at least one antigen, and its use a medicament for the treatment of allergies.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: May 2, 2017
    Assignee: S-TARGET THERAPEUTICS GMBH
    Inventors: Geert Mudde, Gottfried Himmler
  • Patent number: 9636416
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: May 2, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitoni, Susan C. Low
  • Patent number: 9636417
    Abstract: The invention is based on the identification of aminopeptidase N (APN) as the receptor for F4 fimbriae of enterotoxigenic E. coli (ETEC). Based on the observation that oral administration of F4 fimbriae induces a protective intestinal mucosal immune response against a subsequent challenge with F4 ETEC, and the observation that the internalization of said F4fimbriae is clathrin-mediated, the present invention provides the characterization of APN as a target useful in: in an in vitro assay to screen for molecules that are capable to mimic the clathrin-mediated F4 endocytosis; in an in vitro assay to screen for molecules that are capable to modulate the binding of F4 fimbriae with APN; in the development of a carrier for the delivery of antigens/therapeutics, i.e. immunomodulators to the intestinal submucosa or the intestinal mucosa-associated lymphoid tissue, wherein said carrier comprises an APN specific target molecule that mimics the clathrin-mediated F4 endocytosis.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: May 2, 2017
    Assignee: Universiteit Gent
    Inventors: Kristien Rasschaert, Bruno Goddeeris, Eric Cox, Dieter Deforce
  • Patent number: 9636418
    Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: AMGEN INC.
    Inventors: Justin K. Murray, Jerry Ryan Holder, Malgorzata Wanska, Christopher M. Tegley, James R. Falsey, Elizabeth M. Doherty, Leslie P. Miranda
  • Patent number: 9636419
    Abstract: A method of delivering a cargo agent into cytosol of a cell can include: providing the delivery system of one of the embodiments described herein having the first and second delivery platforms; and administering the delivery system to a cell so as to cause targeting of two features on the cell so as to: cause endocytosis of the first and second delivery platforms of the delivery system into a common endosome, destabilize the endosome of the cell having the delivery system, release the cargo agent from the second linker; and release the cargo agent from the destabilized endosome into cytosol of the cell. A method of treating a disease can include: performing the method of method of delivering a cargo agent into cytosol of a cell in a subject having a disease, wherein the cargo agent is a therapeutic agent for the disease.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: May 2, 2017
    Assignees: The Universit of Kansas, Albert Einstein College of Medicine, Inc.
    Inventors: Blake R. Peterson, Liang Xu, Matthew Levy
  • Patent number: 9636420
    Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: May 2, 2017
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 9636421
    Abstract: The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Q1 capable of reacting with a functional group F1 present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1 of a linker-conjugate according to the invention with a functional group F1 of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: May 2, 2017
    Assignee: Synaffix B.V.
    Inventors: Jorge Merijn Mathieu Verkade, Maria Antonia Wijdeven, Petrus Josephus Jacobus Maria Van de Sande, Sander Sebastiaan Van Berkel, Floris Louis Van Delft
  • Patent number: 9636422
    Abstract: A computerized method is disclosed for detecting a brain region with neurodegenerative change and also a brain region with vascular change in the brain of a patient and also an imaging arrangement suitable for this.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: May 2, 2017
    Assignee: SIEMENS AKTIENGESELLSCHAFT
    Inventors: Thorsten Feiweier, Diana Martin, Günther Platsch, Sebastian Schmidt, Kristin Schmiedehausen, Michael Szimtenings
  • Patent number: 9636423
    Abstract: The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: May 2, 2017
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Ralph Weissleder, Peter Panizzi, Jason R. McCarthy
  • Patent number: 9636424
    Abstract: The present invention provides a method of optical electrophysiological probing, including: providing a fluorescing chemical probe; contacting a thick portion of tissue with the fluorescing chemical probe to create a thick portion of treated tissue; applying a first range of wavelengths of electromagnetic radiation to the treated portion of tissue; and detecting a plurality of depth-specific emission wavelengths emitted from the thick portion of treated tissue.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: May 2, 2017
    Assignees: The Research Foundation of State University of New York, University of Connecticut
    Inventors: Arkady M. Pertsov, Arvydas Matiukas, Leslie M. Loew, Joseph P. Wuskell
  • Patent number: 9636425
    Abstract: A device and method for staining the eye of a patient in need of the same includes the introduction, onto the surface of the eye, of a dry powder form at a dye suitable for staining the eye. The dry powder form of the dye is introduced onto the surface of the eye without the use of a substrate at or near the eye's surface.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: May 2, 2017
    Assignee: Focal Point Technologies, LLC
    Inventor: Amir Sahba Jalali
  • Patent number: 9636426
    Abstract: The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatibie macromolecule.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: May 2, 2017
    Inventors: Hiroshi Maeda, Makoto Hashizume, Jun Fang, Hideaki Nakamura, Haibo Qin, Steffen Hackbarth, Masaharu Murata
  • Patent number: 9636427
    Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: May 2, 2017
    Assignee: GUERBET
    Inventors: Dominique Meyer, Claire Corot, Marc Port, Vincent Barbotin, Bruno Bonnemain
  • Patent number: 9636428
    Abstract: The present disclosure is directed to sulfonic esters of metal oxides including those of formulas I and II:
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: May 2, 2017
    Assignees: California Institute of Technology, Children's Hospital of Los Angeles
    Inventors: Carl M. Blumenfeld, Karn Sorasaenee, Harry B. Gray, Robert H. Grubbs
  • Patent number: 9636429
    Abstract: A bracket and tray connection system includes a tray with a plurality of connector holes positioned therein, wherein the tray has an upper surface. A bracket has a base surface positioned proximate to an upper surface of the tray. At least one fastening tab is formed on the base surface of the bracket, wherein the fastening tab extends away from the base surface and through at least one of the connector holes within the tray. An interior corner pocket is formed by the fastening tab and located at least partially between the base surface and the fastening tab. An exterior corner of at least one of the connector holes is positioned with the interior corner pocket. A retainer structure is formed on the base surface of the bracket, wherein the retainer structure engages with the tray to retain the exterior corner positioned within the interior corner pocket.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: May 2, 2017
    Assignee: Symmetry Medical Manufacturing, Inc.
    Inventors: Robert Cushion, Jason Hawkes
  • Patent number: 9636430
    Abstract: A cartridge for a microfluidic delivery system is defined by a longitudinal axis. The cartridge includes a reservoir for containing a fluid composition. The cartridge also includes a nozzle operatively connected with the reservoir. The nozzle is in fluid communication with the reservoir for releasing the fluid composition. The cartridge includes an outer cover operatively connected with the reservoir. The outer cover comprises an orifice that is adjacent to the nozzle. An air flow path is formed by a gap between the reservoir and the outer cover.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: May 2, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Dana Paul Gruenbacher, Martin Diehl, Jannik Scheele, Joseph Edward Scheffelin, Uwe Schober
  • Patent number: 9636431
    Abstract: A dispenser capable of dispensing a fluid via a vertically-oriented piezo device comprises a reservoir containing a fluid to be dispensed, an outlet at a base portion of the reservoir, leading to a dispensing port that comprises a piezo element drivable to vibrate and thereby dispense fluid from the dispensing port, a bleed tube communicating at one end with the dispensing port, extending therefrom to a location above the dispensing port, and including a selectively closeable valve, and a source of below-atmospheric pressure to the portion of the reservoir above the fluid. Embodiments of refills suitable for such a dispensing apparatus are also described.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: May 2, 2017
    Assignee: Vectair Systems Limited
    Inventors: Matthew Teeling, Paul Wonnacott
  • Patent number: 9636432
    Abstract: The presently claimed invention provides a photocatalytic air purification unit, comprising a fin structure and an UV lamp. The fin structure comprises a plurality of fins coated with a layer of photocatalyst, and said fin structure is able to increase the surface area for photocatalyst coating, ultimately increasing air pollutant removal efficiency with minimum air resistance. The air purification unit of the present invention is preferably installed in a HVAC system.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: May 2, 2017
    Assignee: NANO AND ADVANCED MATERIALS INSTITUTE LIMITED
    Inventor: Lok Hang Keung